Companies
From start-ups to market leaders, access critical company intelligence on a global scale
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Bladder cancer is a rapidly evolving field in which new developments are constantly influencing the market.
GlobalData’s Biosimilars market report consists of a slide deck specifying key market-impacting events that have occurred. It also includes an updated Excel-based forecasting model which reflects the expected influence of these events on the market in future.
Several events will drive change to the bladder cancer market landscape, including Spectrum Pharmaceuticals initiating Phase III CONQUER Trial for Apaziquone as adjuvant treatment in patients undergoing TURBT who have low-to-intermediate-risk NMIBC.
Despite being able to keep Tecentriq’s accelerated approval in this setting, Roche still needs to provide confirmatory data in order to receive full FDA approval. GlobalData expects Keytruda to overtake Tecentriq in the bladder cancer market.
Our Biosimilars market report will help you to stay well-informed on the latest news in the bladder cancer space, including regulatory, commercial, and clinical events. Use this report to gain an understanding of how all of these events will impact the projected market forecast.